Changing lives through
innovation
SNAPSHOT
Building a track record of success
25
+
active product programs
150
M+
invested in innovation & product development
5
Research Sites
4
startups
12
revenue- driving agreements
What We Do
Virtici provides the leadership, space and funding support to transform innovations into products...
VALUE CREATION
-
1 Select
-
2 Innovate
-
3 Develop
Virtici leadership brings decades of experience
that intersect innovation and product development.
Virtici Ecosystem
Together we increase our reach and capital, resulting in enhanced innovation, cost-efficient product development, and more valuable medical products for patients.
Areas Of Innovation
Virtici is actively seeking the most innovative product and
platform concepts in the following disease areas.
-
Oncology
-
Microbiome
-
Neurology
-
Autoimmunity
-
Inflammation
-
Infectious Disease
The ASCEND Hub is a Regional Technology Accelerator Hub for the seven Western States: Alaska, Hawaii, Idaho, Montana, Nevada, New Mexico, and Wyoming. The NIH funded program empowers innovators to accelerate biomedical commercialization through entrepreneurial education, mentorship, and technology development funding.
Latest News
Rise Therapeutics Reports Ulcerative Colitis Dose Escalation Clinical Results for R-3750 at the Digestive Disease Week (DDW) Conference in San Diego May 3-6
Rise Therapeutics, a biopharmaceutical company developing precision immunotherapies, today announced that it will report its first clinical results from the completed dose escalation segment of its R-3750 Phase 1 clinical trial in ulcerative colitis at the upcoming DDW conference in San Diego on May 6th.
Read moreRise Therapeutics Receives FDA IND Clearance to Initiate Clinical Testing of R-5780 in Cancer
Rise Therapeutics, a biotechnology company engaged in developing novel oral Immunotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application to proceed with a cancer Phase 1 clinical trial for its program candidate, R-5780. This is Rise Therapeutics’ fourth clinical program to enter patient clinical testing. For separate products, other clinical studies are ongoing for the treatment of ulcerative colitis, rheumatoid arthritis, and type 1 diabetes.
Read moreDose Escalation Completed for Rise Therapeutics’ R-3750 and R-2487 Clinical Trials
Rise Therapeutics, a clinical-stage biotechnology company developing novel oral immunotherapeutic medicines, today announced that it has completed dose escalation enrollment stages for both its R-2487 and R-3750 clinical trials. Both studies will now initiate the planned dose expansion stages to enroll additional patients at fixed doses.
Read moreCeldara Medical Announces Retirement of Lita Nelsen from the Board and Establishment of the Lita Nelsen Prize
Celdara Medical today celebrates the extraordinary contributions of Lita Nelsen as she retires from our Board of Directors after a decade of transformative leadership and visionary guidance. In honor of her unparalleled impact on the field of technology transfer, and her many contributions to our company, Celdara Medical is proud to announce the creation of the Lita Nelsen Prize.
Read moreNew Funding Secured to Support Clinical GMP Manufacturing Expansion Expansion at Rise Therapeutics
Rise Therapeutics announced today that it has received funding from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institute of Health (NIH) to enable infrastructure improvement that will scale GMP production and accelerate quality assurance (QA) and quality control (QC), significantly enhancing its biologics drug manufacturing capabilities.
Read moreCeldara Medical Awarded SBA Regional Innovation Cluster Award to Expand DRIVEN Program Funding to Accelerate Biotech Innovation in New England and Beyond
Celdara Medical, a leader in preclinical biotech development, is excited to announce it has been awarded funding from the U.S. Small Business Administration’s (SBA) Regional Innovation Cluster (RIC) program. This prestigious award will further expand Celdara’s DRIVEN program, designed to support entrepreneurs and early-stage companies in the biotech and life sciences sectors.
Read more